Entero Healthcare Solutions Limited (IN:ENTERO)
:ENTERO
Top Page
Entero Healthcare Solutions Limited
(ENTERO)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹1,145.00
▼(-0.83% Downside)
Action:N/ADate:02/24/26
The score is held back primarily by weak financial quality—cash flow remains consistently negative despite the recent accounting profitability turnaround—alongside bearish technicals with the stock trading below key moving averages. A high P/E further limits upside unless growth and cash conversion improve meaningfully.
Positive Factors
Revenue scaling and return to profitability
Sustained revenue scale and a return to net income across 2024–2025 indicate the business has moved past a growth-at-all-costs phase into operational profitability, underpinning longer-term revenue franchise strength and enabling reinvestment into distribution capabilities and commercial expansion.
Negative Factors
Persistent negative operating and free cash flow
Consistent negative OCF and FCF mean accounting profits have not converted to cash, forcing reliance on external funding or equity; this creates durable liquidity and financing risk, limiting flexibility for investments and exposing the business to working-capital shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue scaling and return to profitability
Sustained revenue scale and a return to net income across 2024–2025 indicate the business has moved past a growth-at-all-costs phase into operational profitability, underpinning longer-term revenue franchise strength and enabling reinvestment into distribution capabilities and commercial expansion.
Read all positive factors
Entero Healthcare Solutions Limited (ENTERO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹51.43B
Dividend YieldN/A
Average Volume (3M)6.57K
Price to Earnings (P/E)40.4
Beta (1Y)0.83
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees3,240
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)8.05
Shares Outstanding43,510,937
10 Day Avg. Volume6,792
30 Day Avg. Volume6,572
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)2.91
Price to Sales (P/S)0.99
P/FCF Ratio-54.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,350.00Price Target Upside16.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)43.77
Revenue Forecast (FY)₹83.86B
Entero Healthcare Solutions Limited Business Overview & Revenue Model
Company Description
Entero Healthcare Solutions Limited engages in the trading of pharmaceutical and surgical products to retail pharmacies, hospitals, nursing homes, and healthcare clinics in India. It is involved in the distribution of medical devices, over the cou...
How the Company Makes Money
Entero primarily makes money through the distribution of pharmaceutical and healthcare products: it purchases products from pharmaceutical/healthcare manufacturers and sells them onward to downstream customers (such as pharmacies, hospitals, and o...
Entero Healthcare Solutions Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
70
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.73B | 50.96B | 39.22B | 33.00B | 25.15B | 17.73B |
| Gross Profit | 5.04B | 2.57B | 3.48B | 1.10B | 2.03B | 1.35B |
| EBITDA | 2.36B | 2.11B | 1.26B | 694.76M | 260.38M | 254.57M |
| Net Income | 1.11B | 948.20M | 391.09M | -115.57M | -299.20M | -155.37M |
Balance Sheet | ||||||
| Total Assets | 28.51B | 27.03B | 23.45B | 14.04B | 11.26B | 8.34B |
| Cash, Cash Equivalents and Short-Term Investments | 3.49B | 3.18B | 7.88B | 1.07B | 1.05B | 828.24M |
| Total Debt | 4.43B | 4.05B | 3.38B | 4.38B | 3.55B | 2.03B |
| Total Liabilities | 10.55B | 9.32B | 7.04B | 7.76B | 5.63B | 3.47B |
| Stockholders Equity | 17.66B | 17.24B | 16.38B | 6.23B | 5.61B | 4.85B |
Cash Flow | ||||||
| Free Cash Flow | -678.96M | -916.38M | -420.28M | -508.34M | -451.32M | -782.13M |
| Operating Cash Flow | -572.73M | -803.24M | -366.12M | -453.15M | -352.66M | -686.84M |
| Investing Cash Flow | -549.08M | 1.82B | -7.05B | -485.95M | -1.62B | -308.69M |
| Financing Cash Flow | -393.12M | -320.99M | 8.63B | 727.64M | 2.11B | 887.13M |
Entero Healthcare Solutions Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹62.38B | 61.22 | ― | 0.68% | 22.36% | 52.00% | |
67 Neutral | ₹81.39B | -247.47 | ― | ― | 17.58% | -38.20% | |
66 Neutral | ₹67.91B | 36.23 | ― | ― | 27.65% | 4.02% | |
54 Neutral | ₹26.39B | 205.09 | ― | 0.92% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹19.73B | 144.78 | ― | ― | 9.78% | 50.78% | |
47 Neutral | ₹51.43B | 40.42 | ― | ― | ― | ― |
* Healthcare Sector Average
IN:ENTERO
Entero Healthcare Solutions Limited
1,182.10
19.50
1.68%
IN:HCG
HealthCare Global Enterprises Ltd.
545.15
22.83
4.37%
IN:MEDIASSIST
Medi Assist Healthcare Services Limited
353.75
-102.10
-22.40%
IN:PANACEABIO
Panacea Biotec Limited
322.05
-129.75
-28.72%
IN:THYROCARE
Thyrocare Technologies Ltd
391.95
162.58
70.88%
IN:YATHARTH
Yatharth Hospital and Trauma Care Services Limited
704.75
251.90
55.63%
Entero Healthcare Solutions Limited Corporate Events
Entero Healthcare Subsidiary Faces Three-Day Drug Licence Suspension
Jan 27, 2026
Entero Healthcare Solutions Limited has disclosed that the Senior Drugs Control Officer cum Licensing Authority, Karnal Zone, has temporarily suspended the drug licenses of its wholly owned subsidiary, Atreja Healthcare Solutions Private Limited, ...
Entero Healthcare’s Statutory Auditor Converts to LLP Without Change in Audit Tenure
Jan 15, 2026
Entero Healthcare Solutions Limited has announced that its statutory auditor, M S K A Associates, Chartered Accountants, has converted from a partnership firm into a Limited Liability Partnership under the Limited Liability Partnership Act, 2008,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.